{
    "organizations": [],
    "uuid": "bd7596c8cee8493cbc48362a7171b0a748329a1e",
    "author": "",
    "url": "https://www.reuters.com/article/brief-kalvista-pharmaceuticals-commences/brief-kalvista-pharmaceuticals-commences-two-clinical-trials-idUSASB0BZVQ",
    "ord_in_thread": 0,
    "title": "BRIEF-Kalvista Pharmaceuticals Commences Two Clinical Trials",
    "locations": [],
    "highlightText": "",
    "language": "english",
    "persons": [],
    "text": " 33 PM / Updated 8 minutes ago BRIEF-Kalvista Pharmaceuticals Commences Two Clinical Trials Reuters Staff \nJan 5 (Reuters) - Kalvista Pharmaceuticals Inc: * KALVISTA PHARMACEUTICALS COMMENCES TWO CLINICAL TRIALS \n* KALVISTA PHARMACEUTICALS INC - TOP-LINE RESULTS ARE EXPECTED IN SECOND HALF OF 2019 FOR KVD001 \n* KALVISTA PHARMACEUTICALS INC - EXPECTS TO PROVIDE AN UPDATE ON STATUS AND PROGRESS OF HAE PORTFOLIO, INCLUDING KVD900, IN MID-2018 Source text for Eikon: Further company coverage:",
    "published": "2018-01-05T14:32:00.000+02:00",
    "crawled": "2018-01-05T14:48:58.004+02:00",
    "highlightTitle": "",
    "preprocessed_text": [
        "pm",
        "updated",
        "minute",
        "ago",
        "pharmaceutical",
        "commences",
        "two",
        "clinical",
        "trial",
        "reuters",
        "staff",
        "jan",
        "reuters",
        "kalvista",
        "pharmaceutical",
        "inc",
        "kalvista",
        "pharmaceutical",
        "commences",
        "two",
        "clinical",
        "trial",
        "kalvista",
        "pharmaceutical",
        "inc",
        "result",
        "expected",
        "second",
        "half",
        "kvd001",
        "kalvista",
        "pharmaceutical",
        "inc",
        "expects",
        "provide",
        "update",
        "status",
        "progress",
        "hae",
        "portfolio",
        "including",
        "kvd900",
        "source",
        "text",
        "eikon",
        "company",
        "coverage"
    ]
}